{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:48:15Z","timestamp":1793731695831,"version":"4.6.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ucl.2022.02.001","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T20:53:58Z","timestamp":1649796838000},"page":"299-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Medical Treatment of Female Sexual Dysfunction"],"prefix":"10.1016","volume":"49","author":[{"given":"Rossella E.","family":"Nappi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Tiranini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bosoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cucinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2022.02.001_bib1","series-title":"Diagnostic and statistical manual of mental disorders","year":"2014"},{"key":"10.1016\/j.ucl.2022.02.001_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.maturitas.2016.09.013","article-title":"Female sexual dysfunction (FSD): Prevalence and impact on quality of life (QoL)","volume":"94","author":"Nappi","year":"2016","journal-title":"Maturitas"},{"key":"10.1016\/j.ucl.2022.02.001_bib3","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/AOG.0b013e3181898cdb","article-title":"Sexual problems and distress in United States women: prevalence and correlates","volume":"112","author":"Shifren","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ucl.2022.02.001_bib4","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.mayocp.2019.01.009","article-title":"The International Society for the Study of Women's Sexual Health Process of Care for the Identification of Sexual Concerns and Problems in Women","volume":"94","author":"Parish","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ucl.2022.02.001_bib5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/14656566.2015.1020791","article-title":"Advances in pharmacotherapy for treating female sexual dysfunction","volume":"16","author":"Nappi","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ucl.2022.02.001_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/13697137.2018.1482647","article-title":"Sexual well-being after menopause: An International Menopause Society White Paper","volume":"21","author":"Simon","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib7","first-page":"1463","article-title":"Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14","volume":"14","author":"Kingsberg","year":"2017","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2022.02.001_bib8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.sxmr.2017.11.002","article-title":"Couplepause: A New Paradigm in Treating Sexual Dysfunction During Menopause and Andropause","volume":"6","author":"Jannini","year":"2018","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.ucl.2022.02.001_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.sxmr.2020.05.001","article-title":"The Evolution of the Female Sexual Disorder\/Dysfunction Definitions, Nomenclature, and Classifications: A Review of DSM, ICSM, ISSWSH, and ICD","volume":"9","author":"Parish","year":"2021","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.ucl.2022.02.001_bib10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1089\/jwh.2019.7865","article-title":"Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment","volume":"29","author":"Kingsberg","year":"2020","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.ucl.2022.02.001_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.maturitas.2009.03.019","article-title":"The challenge of talking about sex: the importance of patient-physician interaction","volume":"63","author":"Brandenburg","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.ucl.2022.02.001_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/13697130903437615","article-title":"Therapeutic options for postmenopausal female sexual dysfunction","volume":"13","author":"Al-Azzawi","year":"2010","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.maturitas.2009.03.012","article-title":"The effects of oestrogen on urogenital health","volume":"63","author":"Lachowsky","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.ucl.2022.02.001_bib14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/GME.0000000000001138","article-title":"The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review","volume":"25","author":"Simon","year":"2018","journal-title":"Menopause"},{"issue":"1 Pt 2","key":"10.1016\/j.ucl.2022.02.001_bib15","first-page":"561","article-title":"Endocrine aspects of women's sexual function","volume":"7","author":"Wierman","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2022.02.001_bib16","first-page":"603","article-title":"The use of estrogen therapy in women's sexual functioning (CME)","volume":"6","author":"Nappi","year":"2009","journal-title":"J\u00a0Sex Med"},{"issue":"4","key":"10.1016\/j.ucl.2022.02.001_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.sxmr.2018.03.005","article-title":"Role of Androgens in Female Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause","volume":"6","author":"Traish","year":"2018","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.ucl.2022.02.001_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvo-vaginal atrophy","volume":"85","author":"Mac Bride","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ucl.2022.02.001_bib19","doi-asserted-by":"crossref","first-page":"101595","DOI":"10.1016\/j.beem.2021.101595","article-title":"The role of hormone therapy in urogenital health after menopause","volume":"35","author":"Nappi","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ucl.2022.02.001_bib20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S2213-8587(15)00284-3","article-title":"Testosterone in women--the clinical significance","volume":"3","author":"Davis","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ucl.2022.02.001_bib21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fendo.2019.00561","article-title":"Addressing Vulvovaginal Atrophy (VVA)\/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women","volume":"10","author":"Nappi","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ucl.2022.02.001_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"IMS Recommendations on women's midlife health and menopause hormone therapy","volume":"19","author":"Baber","year":"2016","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib23","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society","volume":"27","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.ucl.2022.02.001_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/13697137.2010.522875","article-title":"Recommendations for the management of postmenopausal vaginal atrophy","volume":"13","author":"Sturdee","year":"2010","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib25","first-page":"CD009672","article-title":"Hormone therapy for sexual function in perimenopausal and postmenopausal women","volume":"6","author":"Nastri","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ucl.2022.02.001_bib26","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/gme.0b013e31803867a","article-title":"A\u00a0randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women","volume":"14","author":"Shifren","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.ucl.2022.02.001_bib27","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamainternmed.2017.3877","article-title":"Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS)","volume":"177","author":"Taylor","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ucl.2022.02.001_bib28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/GRF.0000000000000657","article-title":"The Role of Progestogens in Menopausal Hormone Therapy","volume":"64","author":"Liu","year":"2021","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ucl.2022.02.001_bib29","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3109\/09513590.2010.495437","article-title":"Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials","volume":"26","author":"Biglia","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ucl.2022.02.001_bib30","first-page":"646","article-title":"LISA study investigators. Tibolone and transdermal E2\/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial","volume":"5","author":"Nijland","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2022.02.001_bib31","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.maturitas.2006.04.014","article-title":"Clitoral circulation in postmenopausal women with sexual dysfunction: a pilot randomized study with hormone therapy","volume":"55","author":"Nappi","year":"2006","journal-title":"Maturitas"},{"key":"10.1016\/j.ucl.2022.02.001_bib32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.fertnstert.2016.10.028","article-title":"Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis","volume":"107","author":"Achilli","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ucl.2022.02.001_bib33","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2213-8587(19)30189-5","article-title":"Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data","volume":"7","author":"Islam","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ucl.2022.02.001_bib34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/13697137.2019.1637079","article-title":"Global Consensus Position Statement on the Use of Testosterone Therapy for Women","volume":"22","author":"Davis","year":"2019","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/13697137.2020.1804547","article-title":"Premature ovarian insufficiency: an International Menopause Society White Paper","volume":"23","author":"Panay","year":"2020","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib36","first-page":"849","article-title":"International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women","volume":"18","author":"Parish","year":"2021","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2022.02.001_bib37","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1210\/jc.2010-2888","article-title":"Clinical review: DHEA replacement for postmenopausal women","volume":"96","author":"Davis","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ucl.2022.02.001_bib38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/13697137.2012.657589","article-title":"The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI","volume":"15","author":"Nappi","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib39","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.maturitas.2015.07.020","article-title":"Update on management of genitourinary syndrome of menopause: A practical guide","volume":"82","author":"Palacios","year":"2015","journal-title":"Maturitas"},{"issue":"8","key":"10.1016\/j.ucl.2022.02.001_bib40","first-page":"CD001500","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","volume":"2016","author":"Lethaby","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ucl.2022.02.001_bib41","first-page":"282","article-title":"Recurrent Uncomplicated Urinary Tract Infections in Women: AUA\/CUA\/SUFU Guideline","volume":"202","author":"Anger","year":"2019","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2022.02.001_bib42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib43","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/GME.0000000000001121","article-title":"Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health","volume":"25","author":"Faubion","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.ucl.2022.02.001_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.maturitas.2020.08.010","article-title":"Genitourinary Syndrome of Menopause: Current Treatment Options in Breast Cancer Survivors - Systematic Review","volume":"143","author":"Mension","year":"2021","journal-title":"Maturitas"},{"key":"10.1016\/j.ucl.2022.02.001_bib45","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/GME.0000000000001497","volume":"27","author":"Hirschberg","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.ucl.2022.02.001_bib46","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/GME.0000000000001177","article-title":"Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues","volume":"26","author":"Labrie","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.ucl.2022.02.001_bib47","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/GME.0000000000000910","article-title":"Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause","volume":"24","author":"Labrie","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.ucl.2022.02.001_bib48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/14656566.2019.1703951","article-title":"An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause","volume":"21","author":"Holton","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ucl.2022.02.001_bib49","first-page":"2401","article-title":"Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy","volume":"12","author":"Labrie","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2022.02.001_bib50","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/13697137.2019.1643180","article-title":"Vulvovaginal atrophy in women after cancer","volume":"22","author":"Cox","year":"2019","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib51","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2018-01345","article-title":"Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors","volume":"103","author":"Davis","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ucl.2022.02.001_bib52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/17446651.2019.1657008","article-title":"Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause","volume":"14","author":"Archer","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.ucl.2022.02.001_bib53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/13697137.2014.975199","article-title":"The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy","volume":"18","author":"Nappi","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/13697137.2014.954996","article-title":"Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial","volume":"18","author":"Constantine","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib55","first-page":"370","article-title":"Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy","volume":"69","author":"Nappi","year":"2017","journal-title":"Minerva Ginecol"},{"key":"10.1016\/j.ucl.2022.02.001_bib56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.maturitas.2020.05.001","article-title":"Potential effectiveness of Ospemifene on Detrusor Overactivity in patients with vaginal atrophy","volume":"138","author":"Novara","year":"2020","journal-title":"Maturitas"},{"key":"10.1016\/j.ucl.2022.02.001_bib57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/09513590.2017.1370645","article-title":"Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene","volume":"34","author":"Schiavi","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ucl.2022.02.001_bib58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mayocp.2016.09.018","article-title":"Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review","volume":"92","author":"Goldstein","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ucl.2022.02.001_bib59","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-015-0288-1","article-title":"The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder","volume":"29","author":"Kingsberg","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ucl.2022.02.001_bib60","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1517\/14656566.2015.1090426","article-title":"Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women","volume":"16","author":"Dhanuka","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ucl.2022.02.001_bib61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJMp1513686","article-title":"FDA approval of flibanserin \u2013 treating hypoactive sexual desire disorder","volume":"374","author":"Joffe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2022.02.001_bib62","first-page":"793","article-title":"Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study","volume":"9","author":"Thorp","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2022.02.001_bib63","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/GME.0000000000000134","article-title":"Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial","volume":"21","author":"Simon","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.ucl.2022.02.001_bib64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.sxmr.2017.06.003","article-title":"Flibanserin: From Bench to Bedside","volume":"5","author":"Dooley","year":"2017","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.ucl.2022.02.001_bib65","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamainternmed.2015.8565","article-title":"Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis","volume":"176","author":"Jaspers","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ucl.2022.02.001_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2020.1707804","article-title":"Evaluation of safety for flibanserin","volume":"19","author":"Clayton","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ucl.2022.02.001_bib67","first-page":"1","article-title":"The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women","author":"Pfaus","year":"2021","journal-title":"CNS Spectr"},{"key":"10.1016\/j.ucl.2022.02.001_bib68","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s40265-019-01187-w","article-title":"Bremelanotide: First Approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ucl.2022.02.001_bib69","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/AOG.0000000000003500","article-title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials","volume":"134","author":"Kingsberg","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ucl.2022.02.001_bib70","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/AOG.0000000000003514","article-title":"Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder","volume":"134","author":"Simon","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ucl.2022.02.001_bib71","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/1060028019899152","article-title":"Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder","volume":"54","author":"Mayer","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ucl.2022.02.001_bib72","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.sxmr.2018.08.003","article-title":"Trazodone in Sexual Medicine: Underused and Overdosed?","volume":"8","author":"Pyke","year":"2020","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.ucl.2022.02.001_bib73","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/14740338.2014.951324","article-title":"Sexual dysfunction associated with major depressive disorder and antidepressant treatment","volume":"13","author":"Clayton","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ucl.2022.02.001_bib74","first-page":"1147","article-title":"Future Targets for Female Sexual Dysfunction","volume":"13","author":"Farmer","year":"2016","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2022.02.001_bib75","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrurol.2009.25","article-title":"Sildenafil citrate for female sexual arousal disorder: a future possibility?","volume":"6","author":"Schoen","year":"2009","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ucl.2022.02.001_bib76","first-page":"2693","article-title":"Influence of sildenafil on genital engorgement in women with female sexual arousal disorder","volume":"9","author":"Leddy","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ucl.2022.02.001_bib77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/13543784.2015.978283","article-title":"Drugs in early clinical development for the treatment of female sexual dysfunction","volume":"24","author":"Belkin","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ucl.2022.02.001_bib78","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/14728214.2018.1527901","article-title":"Expert opinion on existing and developing drugs to treat female sexual dysfunction","volume":"23","author":"Miller","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.ucl.2022.02.001_bib79","doi-asserted-by":"crossref","first-page":"777-9","DOI":"10.1080\/14656566.2019.1582644","article-title":"What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?","volume":"20","author":"Nappi","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2022.02.001_bib80","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/13697137.2013.806402","article-title":"Pharmacogenomics and sexuality: a vision","volume":"16","author":"Nappi","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.ucl.2022.02.001_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246828","article-title":"A\u00a0survival of the fittest strategy for the selection of genotypes by which drug responders and non-responders can be predicted in small groups","volume":"16","author":"H\u00f6hle","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ucl.2022.02.001_bib82","article-title":"Genotype scores predict drug efficacy in subtypes of female\u00a0sexual interest\/arousal disorder: A double-blind, randomized, placebo-controlled cross-over trial","volume":"14","author":"Tuiten","year":"2018","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.ucl.2022.02.001_bib83","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11930-017-0124-3","article-title":"Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder","volume":"9","author":"Both","year":"2017","journal-title":"Curr Sex Health Rep"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014322000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014322000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:56:34Z","timestamp":1758808594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014322000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0094014322000040"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2022.02.001","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Treatment of Female Sexual Dysfunction","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2022.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}